IGC Pharma Q4 2024 GAAP EPS $(0.04), Sales $295.000K Beat $193.000K Estimate
Portfolio Pulse from Benzinga Newsdesk
IGC Pharma reported a Q4 2024 GAAP EPS of $(0.04) and sales of $295,000, which beat the analyst estimate of $193,000 by 52.85%. This represents a 77.71% increase over the same period last year.
June 25, 2024 | 6:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IGC Pharma reported a Q4 2024 GAAP EPS of $(0.04) and sales of $295,000, beating the analyst estimate of $193,000 by 52.85%. This represents a 77.71% increase over the same period last year.
Despite reporting a loss per share, IGC Pharma's significant revenue beat and substantial year-over-year sales growth are likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100